Indylon

Indometacin, the active ingredient in Indylon, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It treats inflammation and pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout flares, and acute pain in adults.

GNH USA supplies Indylon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indometacin is used to manage inflammatory and painful conditions affecting the musculoskeletal system.

Rheumatoid arthritis: reduces joint inflammation and pain, improving function. Osteoarthritis: alleviates chronic joint discomfort and swelling. Ankylosing spondylitis: diminishes spinal inflammation and stiffness. Gout flares: provides rapid relief of acute gouty arthritis symptoms. Acute pain and inflammation: controls sudden onset pain from injuries or surgical procedures.

Indometacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset, including nausea and dyspepsia. - Headache or dizziness. - Mild skin rash or itching. - Elevated liver enzymes.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Acute renal impairment or failure. - Severe hepatic injury. - Life‑threatening skin reactions such as Stevens‑Johnson syndrome. - Anaphylactic or severe allergic reactions. - Blood dyscrasias including agranulocytosis.

Before prescribing Indometacin, clinicians should evaluate patient risk factors and monitor for adverse events.

Assess renal function: check baseline creatinine and monitor during therapy. Evaluate hepatic status: perform liver function tests before and periodically. Screen for gastrointestinal risk: avoid in patients with active ulcers or a history of GI bleeding. Avoid in known hypersensitivity: discontinue if severe allergic reactions occur. Store at room temperature: keep in the original container, protect from moisture and heat.

Indometacin can alter the efficacy or safety of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Lithium: heightened lithium toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function. - Diuretics: risk of electrolyte imbalance and renal impairment. - Methotrexate: possible increased toxicity due to reduced clearance.